Pharmicell said that it has filed an investigational new drug application to conduct the clinical trials of Cellgram-DC, a treatment for ovarian cancer, to the Ministry of Food and Drug Safety.
The trial will use dendritic cells differentiated from the patient's bone marrow to evaluate the safety, tumor-specific immune response, and efficacy on metastatic or recurrent epithelial ovarian cancer.
"Myeloid dendritic cells, the main component of Cellgram-DC, are known to have the best inherent function of dendritic cells found in living organisms," a company official said. "Using our company's technology, we will develop safe and effective anti-cancer immune cell therapies to improve not only the quality of life of patients but also decrease their economic burdens."
Ovarian cancer affects women worldwide, and the number of new ovarian cancer patients worldwide is around 200,000 per year. Although the mortality rate for ovarian cancer has improved slightly over the past decade, the disease still has the highest recurrence and mortality rates among gynecological tumors.
<© Korea Biomedical Review, All rights reserved.>